PubMed Health⌕ Search

Biomedical subjects

G A Melilli

Publications and source records attributed to G A Melilli.

22 records · Page 2Linked to original sources
PubMed1998

Prolonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report.

Malignant mixed müllerian tumors (MMMT) of the ovary are rare, aggressive and rapidly progressive tumors. According to the available literature, the presence of metastatic disease rarely permits long term survival. We report on a 64-year old patient with stage IV ovarian MMMT who achieved a surgically-documented complete response (CR) after 6 cycles of carboplatin, mesna, ifosfamide, cis-platin. Pelvic recurrence was diagnosed 14 months later; the patient received 6 cycles of the same regimen used as first-line chemotherapy which resulted in a second complete response lasting for 4 months. The patient died 37 months after initial diagnosis due to intestinal occlusion. In the current case Ca 125 was significantly increased at clinical presentation of disease but not at the time of recurrence.

Animals↗
PubMed1998

[Sarcoma of the endometrial stroma].

BACKGROUND: To evaluate the most important risk factors and the efficacy of endometrial stromal sarcoma therapy. METHODS: During a period of 9 years, 5 cases of ESS have been observed at the IInd Obstetrical and Gynecological Institute of the University of Bari. The patients were staged according to the FIGO classification of endometrial carcinoma and studied from an epidemiological, histopatological and clinical point of view. All patients firstly received uterine courettage and then total simple laparohysterectomy. In 4 cases bilateral salpingo-oophorectomy and then polychemotherapy. Only in 1 case total hysterectomy and monolateral salpingo-oophorectomy were performed. RESULTS: Two patients were affected by low grade ESS malignancy respectively at Ib and Ic stage and received only surgery. High grade ESS malignancy was diagnosed in 3 patients at stage IIIa and they received surgery followed by chemotherapy. These 3 patients survived for 14, 25 and 30 months. The other two are still alive, with no evidence of the disease at 25 and 36 months. CONCLUSION: ESS is a rare neoplasm; the low grade malignancy may survive from 80-100%, while the high ones can have a fatal prognosis with exitus in 12-30 months.

Adult↗
PubMedDate not supplied

[Clinical experience with uterine sarcoma].

BACKGROUND: To report and compare personal experience with international literature on uterine sarcomas. METHODS: 17 cases of uterine sarcomas diagnosed during seven years in our Institute, have been clinically histopathologically, prognostically and therapeutically analyzed. RESULTS: 10 cases of LMS, 6 of MMT, and 1 of ESS have been found. Women affected were mostly 42 to 84 years old. Most of the youngest patients were affected by LMS, while the oldest by MMT. Almost all of them were in menopause and pluriparae. The symptomatology consisted mainly of vaginal bleeding (58.9%). The diagnosis was preoperative for MMT and ESS; in 8 cases it was adopted for stage I, surgery and RT for stage II, surgery, RT and chemotherapy for a woman of stage III, and for the last two surgery and chemotherapy. The patients of stage III and IV survived respectively 8 and 10 months; three patients in stage I still have a 5 years survival and the other are still in follow-up. CONCLUSION: This work is a clinical contribution since the rarity of these neoplasms does not allow the standardization of a diagnostical and therapeutical iter and consequently the improvement of prognosis.

Adult↗